70.0 B

Thymosin Alpha-1

Also known as: Zadaxin, TA-1

Strong Clinical Evidence Category 2 Restricted
Research Evidence 90.0/100
Safety Profile 50.0/100

71 Clinical Trials

Unknown: 4 PHASE4: 12 PHASE3: 10 PHASE2: 25 PHASE1, PHASE2: 3 PHASE1: 5 NA: 11 EARLY_PHASE1: 1

Showing 5 of 71 trials.

20 Research Papers

Showing 5 of 20 papers by citation count.

FDA Data

Not FDA-Approved

Thymosin Alpha-1 has not been evaluated by the FDA for safety or efficacy. It is not approved for human therapeutic use in the United States.

This peptide is classified as FDA Category 2 — it is prohibited from use in compounding pharmacies effective 2024. Obtaining it requires unregulated sources.

Frequently Asked Questions

Is Thymosin Alpha-1 FDA approved?
No, Thymosin Alpha-1 is not FDA approved. It is classified as FDA Category 2 and is banned from compounding pharmacies.
How many clinical trials has Thymosin Alpha-1 been studied in?
Thymosin Alpha-1 has been studied in 71 registered clinical trials. CheckPeptides tracks phase, status, and sponsor data for each trial.
What is the trust score for Thymosin Alpha-1?
Thymosin Alpha-1 has a CheckPeptides trust score of 70.0/100 (grade: B). This score is based on clinical trial volume, research paper quality, FDA data, and evidence classification.
Last verified: April 7, 2026

Quick Facts

Classification
Thymic peptide
Regulatory Status
N/A

Score Breakdown

Research Evidence 90.0/100
Safety Profile 50.0/100

Evidence Summary

Clinical Trials
71
Research Papers
20
Trust Score
70.0/100
Grade
B

Compare Peptides

See how Thymosin Alpha-1 stacks up against similar peptides.

View Comparisons
← Browse all peptides